{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:16:22Z","timestamp":1791832582990,"version":"4.3.4"},"reference-count":32,"publisher":"Media Sphere Publishing House","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rus. Ann. Ophthal."],"published-print":{"date-parts":[[2025,9,8]]},"abstract":"<jats:p>Objective. This study evaluated the effect of sequential therapy with different dosages of Mexidol on the stabilization of glaucomatous optic neuropathy (GON) in patients with primary open-angle glaucoma (POAG). Material and methods. The study included 80 patients (160 eyes) with stage II and III POAG, randomized into three groups comparable by age, gender, and distribution of glaucoma stage. All patients received sequential therapy with Mexidol (14 days parenterally followed by 90 days orally). Groups were defined as follows: group 1 \u2014 \u201chigh dosage\u201d, group 2 \u2014 \u201clow dosage\u201d, and group 3 \u2014 \u201cplacebo\u201d. Before therapy initiation and at completion, static automated perimetry was used to determine the mean deviation (MD) and pattern standard deviation (PSD) of retinal light sensitivity, as well as the number of first- and second-order scotomas. Subgroup analysis was performed based on treatment response. Glaucoma progression during therapy was analyzed using the Kaplan-Meier method. Results. A statistically significant improvement in MD compared with baseline was observed after the course of therapy in both the high- and low-dose groups for moderate (p&lt;0.001) and advanced (p&lt;0.05) stages of POAG. There was a trend toward PSD improvement in the groups of both dosages, but absent in the placebo group. Unlike the treatment groups, the placebo group showed a negative trend toward an increase in relative first- and second-order scotomas. Subgroup comparison revealed significant differences among the \u201chigh dosage\u201d, \u201clow dosage\u201d, and \u201cplacebo\u201d groups (p=0.002, Pearson\u2019s \u03c7\u00b2 test). Kaplan-Meier analysis demonstrated a high probability of glaucoma progression in the \u201cplacebo\u201d group and a significantly lower probability (p&lt;0.01) in both \u201chigh dosage\u201d and \u201clow dosage\u201d Mexidol groups. Conclusion. Mexidol therapy improves retinal light sensitivity, stabilizes the number of relative first- and second-order scotomas, and reduces the likelihood of GON progression. The dose-dependent effect of Mexidol was demonstrated.<\/jats:p>","DOI":"10.17116\/oftalma202514104149","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T14:25:10Z","timestamp":1757341510000},"page":"49","source":"Crossref","is-referenced-by-count":1,"title":["The possibilities of antioxidant neuroretinoprotection in the treatment of primary open-angle glaucoma"],"prefix":"10.17116","volume":"141","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6495-7173","authenticated-orcid":false,"given":"E.A.","family":"Egorov","sequence":"first","affiliation":[{"name":"Pirogov Russian National Research Medical University","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9606-0566","authenticated-orcid":false,"given":"A.V.","family":"Kuroyedov","sequence":"additional","affiliation":[{"name":"Pirogov Russian National Research Medical University","place":["Moscow, Russia"]},{"name":"Mandryka Central Military Clinical Hospital","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0368-296X","authenticated-orcid":false,"given":"N.A.","family":"Gavrilova","sequence":"additional","affiliation":[{"name":"Russian University of Medicine","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9173-4754","authenticated-orcid":false,"given":"A.E.","family":"Yavorskiy","sequence":"additional","affiliation":[{"name":"V.P. Vykhodtsev Clinical Ophthalmological Hospital","place":["Omsk, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1488-0377","authenticated-orcid":false,"given":"E.A.","family":"Gornostaeva","sequence":"additional","affiliation":[{"name":"OOO Diagnosticheskij tsentr Zreniye","place":["Saint Petersburg, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6743","reference":[{"key":"key-10.17116\/oftalma202514104149-1","doi-asserted-by":"publisher","DOI":"10.33029\/9704-7661-1-LFP-2023-1-1032"},{"key":"key-10.17116\/oftalma202514104149-2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ogla.2020.09.002"},{"key":"key-10.17116\/oftalma202514104149-3","unstructured":"World Health Organization. World report on vision. 2019. Accessed May 19, 2025.  https:\/\/www.who.int\/publications\/i\/item\/world-report-on-vision"},{"key":"key-10.17116\/oftalma202514104149-4","unstructured":"Egorov EA, Brezhnev AYu, Egorov AE. Neuroprotection in glaucoma: current opportunities and prospects. Russian Journal of Clinical Ophthalmology. 2014;14(2):108-112. (In Russ.)"},{"key":"key-10.17116\/oftalma202514104149-5","doi-asserted-by":"publisher","DOI":"10.32364\/2311-7729-2023-23-1-47-53"},{"key":"key-10.17116\/oftalma202514104149-6","doi-asserted-by":"publisher","DOI":"10.32364\/2311-7729-2019-19-3-128-135"},{"key":"key-10.17116\/oftalma202514104149-7","doi-asserted-by":"publisher","DOI":"10.32364\/2311-7729-2024-24-4-1"},{"key":"key-10.17116\/oftalma202514104149-8","doi-asserted-by":"publisher","DOI":"10.32364\/2311-7729-2025-25-1-2"},{"key":"key-10.17116\/oftalma202514104149-9","doi-asserted-by":"publisher","DOI":"10.17116\/oftalma202013606157"},{"key":"key-10.17116\/oftalma202514104149-10","doi-asserted-by":"publisher","DOI":"10.17116\/oftalma202313905196"},{"key":"key-10.17116\/oftalma202514104149-11","doi-asserted-by":"publisher","DOI":"10.17116\/oftalma2021137052289"},{"key":"key-10.17116\/oftalma202514104149-12","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2013.294"},{"key":"key-10.17116\/oftalma202514104149-13","doi-asserted-by":"publisher","DOI":"10.3390\/cells12091272"},{"key":"key-10.17116\/oftalma202514104149-14","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2021.100998"},{"key":"key-10.17116\/oftalma202514104149-15","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11050888"},{"key":"key-10.17116\/oftalma202514104149-16","doi-asserted-by":"publisher","DOI":"10.25700\/NJG.2021.01.01"},{"key":"key-10.17116\/oftalma202514104149-17","doi-asserted-by":"publisher","DOI":"10.25700\/NJG.2020.03.02"},{"key":"key-10.17116\/oftalma202514104149-18","unstructured":"Egorov EA, Erichev VP, Kuroedov AV, Petrov SYu, Antonov AA. Tonometric intraocular pressure reference values in healthy population. National Journal Glaucoma. 2018;17(2):91-98. (In Russ.)"},{"key":"key-10.17116\/oftalma202514104149-19","doi-asserted-by":"publisher","DOI":"10.17116\/oftalma202414004148"},{"key":"key-10.17116\/oftalma202514104149-20","unstructured":"Klinicheskie rekomendatsii \u00abGlaukoma pervichnaya zakrytougol\u2019naya\u00bb. 2024. (In Russ.). Accessed May 19, 2025. https:\/\/cr.minzdrav.gov.ru\/preview-cr\/631_2"},{"key":"key-10.17116\/oftalma202514104149-21","unstructured":"Klinicheskie rekomendacii \u00abGlaukoma pervichnaya otkrytougol\u2019naya\u00bb. 2024. (In Russ.). Accessed May 19, 2025. https:\/\/cr.minzdrav.gov.ru\/preview-cr\/96_2"},{"key":"key-10.17116\/oftalma202514104149-22","doi-asserted-by":"publisher","DOI":"10.17116\/oftalma202514101183"},{"key":"key-10.17116\/oftalma202514104149-23","doi-asserted-by":"publisher","DOI":"10.17116\/oftalma2022138051122"},{"key":"key-10.17116\/oftalma202514104149-24","doi-asserted-by":"publisher","DOI":"10.17116\/oftalma202313904135"},{"key":"key-10.17116\/oftalma202514104149-25","doi-asserted-by":"publisher","DOI":"10.17116\/oftalma2016132136-42"},{"key":"key-10.17116\/oftalma202514104149-26","unstructured":"Egorov EA, Obruch BV, Oleinik AI, Bordashevskaya LS, Kurbanova MR. The use of the drug Mexidol in patients with dystrophic diseases of the posterior segment of the eye. Russian Journal of Clinical Ophthalmology. 2009; 10(4):145-148. (In Russ.)"},{"key":"key-10.17116\/oftalma202514104149-27","unstructured":"Malyshev VE, Salnikova OI. The experience of using the drug Mexidol in the complex outpatient treatment of patients with degenerative-dystrophic eye diseases. Bulletin of Experimental Biology and Medicine. 2006;(1):55-57. (In Russ.)"},{"key":"key-10.17116\/oftalma202514104149-28","unstructured":"Volchegorskiy IA, Tur EV, Solyannikova OV, Rykun VS, Sumina MS, Dmitrienko VN, Berdnikova EV. Efficacy of 3-hydroxypyridine and succinic acid derivatives in the complex treatment of primary open-angle glaucoma. Experimental and Clinical Pharmacology. 2012;75(7):20-26. (In Russ.)"},{"key":"key-10.17116\/oftalma202514104149-29","unstructured":"Egorov EA, Gvetadze AA, Davydova NG. Antioxidant drug in neuroprotective therapy for glaucoma. Russian Annals of Ophthalmology. 2013;2:67-69. (In Russ.)"},{"key":"key-10.17116\/oftalma202514104149-30","unstructured":"Egorov EA, Davydova NG, Romanenko IA, Novikova ND. Mexidol in the complex treatment of glaucoma. Russian Journal of Clinical Ophthalmology. 2011;12(3):3-6. (In Russ.)"},{"key":"key-10.17116\/oftalma202514104149-31","unstructured":"Afonina EA, Levko MA, Chekurova LV, Kosacheva TI. Our experience of using mexidol in the complex treatment of patients with primary open-angle glaucoma. In: Russian glaucoma school. Conference \u201cGlaucoma: theory and practice\u201d. St. Petersburg: Chelovek i ego zdorov\u2019e; 2013;8:33-37. (In Russ.)"},{"key":"key-10.17116\/oftalma202514104149-32","doi-asserted-by":"publisher","DOI":"10.33978\/2307-3586-2022-18-11-52-56"}],"container-title":["Russian Annals of Ophthalmology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T14:25:31Z","timestamp":1757341531000},"score":1,"resource":{"primary":{"URL":"https:\/\/mediasphera.ru\/issues\/vestnik-oftalmologii\/2025\/4\/10042465X2025041049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,8]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,9,8]]}},"alternative-id":["10.17116\/oftalma202514104149"],"URL":"https:\/\/doi.org\/10.17116\/oftalma202514104149","relation":{},"ISSN":["0042-465X"],"issn-type":[{"value":"0042-465X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,8]]}}}